BR112022015571A2 - Formulação de daptomicina. - Google Patents

Formulação de daptomicina.

Info

Publication number
BR112022015571A2
BR112022015571A2 BR112022015571A BR112022015571A BR112022015571A2 BR 112022015571 A2 BR112022015571 A2 BR 112022015571A2 BR 112022015571 A BR112022015571 A BR 112022015571A BR 112022015571 A BR112022015571 A BR 112022015571A BR 112022015571 A2 BR112022015571 A2 BR 112022015571A2
Authority
BR
Brazil
Prior art keywords
formulation
daptomicin
daptomycin
solid formulation
present disclosure
Prior art date
Application number
BR112022015571A
Other languages
English (en)
Portuguese (pt)
Inventor
Fumic Barbara
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of BR112022015571A2 publication Critical patent/BR112022015571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022015571A 2020-02-28 2021-02-26 Formulação de daptomicina. BR112022015571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Publications (1)

Publication Number Publication Date
BR112022015571A2 true BR112022015571A2 (pt) 2022-09-27

Family

ID=74797935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015571A BR112022015571A2 (pt) 2020-02-28 2021-02-26 Formulação de daptomicina.

Country Status (9)

Country Link
US (1) US12629337B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110303A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516957A (cg-RX-API-DMAC7.html)
CN (2) CN118873500A (cg-RX-API-DMAC7.html)
AU (1) AU2021227095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022015571A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010378A (cg-RX-API-DMAC7.html)
WO (1) WO2021170807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208343B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
WO2026111848A1 (en) * 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2013103801A1 (en) 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
NO2887953T3 (cg-RX-API-DMAC7.html) 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2016098009A1 (en) 2014-12-16 2016-06-23 Dr. Reddy’S Laboratories Limited Lyophilized injectable compositions of daptomycin
CN106943587B (zh) 2016-01-06 2021-06-22 山东新时代药业有限公司 一种注射用达托霉素冻干粉针及其制备工艺
US11759497B2 (en) * 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation

Also Published As

Publication number Publication date
JP2025142200A (ja) 2025-09-30
US20230068866A1 (en) 2023-03-02
AU2021227095A1 (en) 2022-08-25
EP4110303A1 (en) 2023-01-04
MX2022010378A (es) 2022-09-21
CN118873500A (zh) 2024-11-01
WO2021170807A1 (en) 2021-09-02
CN115038431B (zh) 2024-08-09
US12629337B2 (en) 2026-05-19
JP2023516957A (ja) 2023-04-21
AU2021227095B2 (en) 2024-02-22
CA3168727A1 (en) 2021-09-02
CN115038431A (zh) 2022-09-09
ZA202208343B (en) 2024-11-27

Similar Documents

Publication Publication Date Title
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BR112012018023A2 (pt) formulações líquidas que contêm anticorpo estabilizado.
MX352892B (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
PE20141029A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR112013017884A2 (pt) varredura de microcolônia encapsulada com gel
BR112020003467B8 (pt) Método para preparar uma composição fermentada, e, composição fermentada
BR112015032800A2 (pt) “processo para a produção de um anticorpo”
BR112014002624A8 (pt) Microorganismo recombinante e cultura de microorganismo recombinante
BR112022012721A2 (pt) Preenchimentos dérmicos com mistura física de ah-colágeno
BR112022003169A2 (pt) Formulações de anticorpo anti-il-23p19
MX2022010378A (es) Formulacion de daptomicina.
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
BR112017016077A2 (pt) ?composição e método para uso no aumento da eficácia do enxerto de células-tronco hematopoiéticas após transplante?
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
MX2020001885A (es) Formulaciones de daptomicina.
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
BR112022009568A2 (pt) Composição de poliuretano, e, revestimento
BR112022006439A2 (pt) Métodos para produção de bioterapêuticos com estabilidade aumentada por otimização de sequência
CL2019000766A1 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.
EA201692454A1 (ru) Твердая фосфатная соль и способ ее получения
CL2022003641A1 (es) Método para el tratamiento de composiciones que contienen proteínas
BR112022000392A2 (pt) Composição compósita, estrutura moldada e método para fazer uma estrutura moldada
BR112022022006A2 (pt) Composições para vasos de plantas biodegradáveis.
BR112017015608A2 (pt) análogos de insulina com propriedades de sinalização seletiva e reduzida mitogenicidade
MX382576B (es) Composiciones alimenticias semihúmedas que mantienen una textura blanda.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]